meropenem and Multiple-Sclerosis--Relapsing-Remitting

meropenem has been researched along with Multiple-Sclerosis--Relapsing-Remitting* in 1 studies

Other Studies

1 other study(ies) available for meropenem and Multiple-Sclerosis--Relapsing-Remitting

Article	Year
Pulmonary Nocardia beijingensis infection associated with the use of alemtuzumab in a patient with multiple sclerosis. Multiple sclerosis (Houndmills, Basingstoke, England), 2017, Volume: 23, Issue:6 Nocardia is a Gram-positive aerobic pathogen that usually affects immunocompromised patients. We report a case of pulmonary infection caused by a rare Nocardia species, Nocardia beijingensis, in a 50-year-old woman who had received alemtuzumab for the treatment of her multiple sclerosis. The invasive pulmonary infection was successfully treated with meropenem. Topics: Alemtuzumab; Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized; Female; Humans; Immunocompromised Host; Immunologic Factors; Meropenem; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Nocardia Infections; Pneumonia, Bacterial; Sepsis; Thienamycins	2017

Article

Year

Pulmonary Nocardia beijingensis infection associated with the use of alemtuzumab in a patient with multiple sclerosis.

Multiple sclerosis (Houndmills, Basingstoke, England), 2017, Volume: 23, Issue:6

Nocardia is a Gram-positive aerobic pathogen that usually affects immunocompromised patients. We report a case of pulmonary infection caused by a rare Nocardia species, Nocardia beijingensis, in a 50-year-old woman who had received alemtuzumab for the treatment of her multiple sclerosis. The invasive pulmonary infection was successfully treated with meropenem.

Topics: Alemtuzumab; Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized; Female; Humans; Immunocompromised Host; Immunologic Factors; Meropenem; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Nocardia Infections; Pneumonia, Bacterial; Sepsis; Thienamycins

2017